Iconovo AB and Lonza initiated a collaboration to develop spray-dried formulations of an intranasal biologic for Iconovo’s proprietary intranasal device ICOone Nasal®. This project, with a reformulated substance for obesity, is the first in Iconovo’s strategic initiative to reformulate known pharmaceuticals and replace injections and oral treatments with inhalation.
According to the agreement, Lonza will develop spray-dried formulations for administration in the ICOone Nasal® device at its Bend (US) site, which specializes in addressing bioavailability challenges and modulating pharmacokinetics to meet target product profiles. The collaboration aims to identify the ideal product properties concerning particle size, stability, and device compatibility while preserving biological activity.
The Iconovo inhaler platform, ICOone Nasal®, is a unique and proprietary nasal device that releases the dose when the user inhales. One inhaler and an inhale through each nostril should administer a standard dose of the biologic compound, challenging the need for today’s injected formulation.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!